	US 12,234,472 B2
	Eukaryotic cells comprising adenovirus-associated virus polynucleotides
Michael Goren, Tarrytown, NY (US); Yu Zhao, Willison Park, NY (US); Alexandros Strikoudis, New York, NY (US); Darya Burakov, Tarrytown, NY (US); and Gang Chen, Yorktown Heights, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 18, 2022, as Appl. No. 18/047,341.
Claims priority of provisional application 63/256,730, filed on Oct. 18, 2021.
Prior Publication US 2023/0193312 A1, Jun. 22, 2023
Int. Cl. C12N 15/85 (2006.01); C07K 14/005 (2006.01); C12N 15/67 (2006.01)

CPC C12N 15/85 (2013.01) [C07K 14/005 (2013.01); C12N 15/67 (2013.01); C12N 2830/42 (2013.01); C12N 2830/50 (2013.01); C12N 2840/203 (2013.01)]

15 Claims

1. A eukaryotic cell from a eukaryotic cell line, wherein the eukaryotic cell comprises a polynucleotide comprising in order (i) a promoter, (ii) an intron, (iii) a first internal ribosome entry site, (iv) a first AAV Cap gene, (v) a second internal ribosome entry site, (vi) a second AAV Cap gene, and (vii) a polyadenylation site, wherein (i) to (vii) are operably linked.